Effective Practices in MYELOFIBROSIS Programs Association of Community

First Page		Document Content
Date: 2015-03-27 09:37:40 Thrombocytosis Oncology Cancer organizations Medicine Myelofibrosis Essential thrombocytosis		Effective Practices in MYELOFIBROSIS Programs Association of Community Add to Reading List Source URL: www.accc-cancer.org Download Document from Source Website File Size: 592,20 KB Share Document on Facebook

	HAEMATOLOGY AUDIT TEMPLATE DocID: 1pL02 - View Document
	Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016 DocID: 1pn6V - View Document
	1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62 DocID: 1ohLr - View Document
	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard DocID: 19YPO - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document